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We evaluated dietary intake and nutritional-inflammation status in ninety-six renal transplant recipients, 7.2 ± 5.0 years after
transplantation. Patients were classified as normoweight (NW), overweight (OW), and obese (OB), if their body mass index was
between 18.5 and 24.9, 25.0 and 29.9, and ≥30 kg/m2, respectively. Food composition tables were used to estimate nutrient intakes.
The values obtained were compared with those recommended in current nutritional guidelines. 52% of the patients were NW, 29%
were OW, and 19% were OB. Total energy, fat, and dietary n-6 PUFAs intake was higher in OB than in NW. IL-6 and hs-CRP were
higher in OB than in NW. The prevalence of multidrug regimen was higher in OB. In all patients, total energy, protein, saturated
fatty acids, and sodium intake were higher than guideline recommendations. On the contrary, the intake of unsaturated and n-6 and
n-3 polyunsaturated fatty acids and fiber was lower than recommended. In conclusion, the prevalence of obesity was high in our
patients, and it was associated with inflammation and the assumption of multiple cardiovascular and antidiabetic drugs. Dietary
intake did not meet nutritional recommendations in all patients, especially in obese ones, highlighting the need of a long-term
nutritional support in renal transplant recipients.
1. Introduction
The outcome of a successful renal transplantation (RT)
depends on immunological and nonimmunological factors
that may lead to progressive graft damage and, ultimately, to
chronic allograft dysfunction (CAD). Besides a valid clini-
cal assessment and a balanced immunosuppressive therapy,
patients compliance to a correct lifestyle may help preventing
CAD. In particular, healthy eating habits in accordance with
current dietary recommendations represent an effective sec-
ondary prevention strategy that reduces the risk of renal and
cardiovascular diseases [1–7]. This is particularly important
in renal transplant recipients [7–9]. In these subjects, an
increase in body weight commonly occurs. Several factors
are responsible for this phenomenon; among them the most
relevant are the transition from restricted dialysis dietary
regimen to unrestricted diet, the feeling of well-being, and
the increase in appetite mostly due to steroid administration
[10]. Many patients become obese during the first years after
RT [11]. This causes an increase in the risk of developing
arterial hypertension, cardiovascular disorders, new-onset
diabetes mellitus, and hyperlipidemia [12]. All these factors
lead to accelerated CAD [13]. Therefore, in renal transplant
recipients, it seems crucial to implement as early as possible
an effective nutrition program to achieve and maintain a cor-
rect body weight [14] with the final goal of improving graft
survival. A further advantage associated with a healthy diet
could be the reduction of the microinflammation that is
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commonly observed in transplant recipients [15]. Evidence is
emerging, indeed, that dietarymanipulationmay beneficially
influence inflammatory and even autoimmune diseases [16].
In particular, it has been suggested that the supplementa-
tion with anti-inflammatory n-3 polyunsaturated fatty acids
(PUFAs) could exert beneficial effect in preserving the renal
function in renal transplant recipients. On the contrary, n-6
PUFAsmay act as a proinflammatory substance andmay even
promote kidney injury [17, 18].
Previous studies in renal transplant recipients focused on
the effects of immunosuppressive drugs on body composition
[19] or tried to identify the characteristics of patients at
risk for excessive weight gain [20]. On the contrary, limited
information is available on nutrient intake, and no study
evaluated yet the intake of n-3 and n-6 PUFAs and their ratio
in these patients. In addition, no data is available for the
impact of the nutritional status on systemic inflammation and
drug consumption in renal allograft recipients. Therefore, in
the present study, we assessed dietary intake, with particular
reference to n-3 and n-6 PUFA intake, in a cohort of long-
term renal transplant patients, and we compared the results
obtained with current nutrition recommendations. We also
evaluated the association between nutritional, and inflam-
matory status and cardiovascular and antidiabetic drug
assumption in these patients.
2. Patients and Methods
2.1. Patients. A total of 96 patients were enrolled from
September 2012 to December 2012 among the recipients
of a renal transplant from a cadaver donor coming to the
Nephrology Unit of the Federico II University of Naples
as part of the periodic follow-up after transplantation
for immunosuppressive drug monitoring and clinical and
metabolic evaluation. Enrollment was performed according
to the inclusion and exclusion criteria reported below and
independently from the time elapsed from kidney transplan-
tation.
The mean transplant vintage was 7.2 ± 5.0 years. All the
patients had a successful transplantation and none of them
had to be subjected to a second organ transplant. Inclusion
criteria were as follows: age > 18 years, stable renal function
in the last 3 months, absence of infection, cancer, or any acute
illness in the last 2 months.The immunosuppressive regimen
of all the patients included 4mg/day of methylprednisolone
plus cyclosporine (CYA) or tacrolimus (FK) and, in some
patients, mycophenolate mofetil (MMF). Drug therapy was
adjusted to reach trough CYA and FK blood levels of 150–200
and 6–10mg/mL, respectively.
At the time of the enrollment, a comprehensive nutri-
tional evaluation was performed as detailed here in after. A 7-
day food diary was given to the patients who were instructed
on how to fill it out at home. When the patients came back
after a week to return the diary, a blood sample was collected
for the determination of the biochemical markers of the
nutritional and inflammatory status specified below. All the
subjects gave their informed consent to the study that was
approved by the Ethical Committee of the Medical School of
the University Federico II of Naples.
2.2. Assessment of the Nutritional Status. The nutritional
status of the patients was determined by measuring their
bodymass index (BMI), by assessing their body composition,
and by evaluating specific biochemical nutritional markers in
their plasma.
BMI was calculated for each patient as the body mass
divided by the square of height (kg/m2) [21]. According to
the BMI classification of the World Health Organization,
patients having a BMI between 18.5 and 24.9 were classified
as Normalweight (NW), those with a BMI between 25.0 and
29.9 as Overweight (OW), and those with a BMI higher than
or equal to 30 as Obese (OB). Waist to hip ratio (WHR) was
measured as an indirect index of visceral obesity. WHR was
measured by placing a measuring tape at the level of the
umbilicus whereas the measuring tape was placed at the level
of the widest part of the hip to measure hip circumference.
Participants were considered centrally obese ifWHRwas 0.95
or over for male and 0.85 or over for female.
Body composition was assessed by bioelectrical
impedance analysis (BIA). A tetrapolar 50 kHz bioelectrical
impedance analyzer (BIA 101 RJL, Akern Bioresearch,
Firenze, Italy) was used to measure resistance (R) and reac-
tance (Xc). These parameters were converted by the software
provided by themanufacturer in estimates of total bodywater
(TBW), fat mass (FM), and fat free mass (FFM) [22, 23].
The following chemicals were assessed in peripheral
blood samples as they are sensitive indicators of the nutri-
tional status: blood urea nitrogen (BUN), creatinine, glucose,
total cholesterol, high-density lipoprotein cholesterol (HDL-
chol), low-density lipoprotein cholesterol (LDL-chol), trigly-
cerides, albumin, calcium, and phosphorus.
2.3. Dietary Assessment. Caloric intake and diet composition
were determined through the analysis of a 7-day food diary
that patients were required to fill out at home after each
meal [24]. These data were examined by expert dietitians
who calculated total daily intake and the percent contri-
bution of micro- and macronutrients using validated food
composition tables [25–27]. Total n-3 polyunsaturated fatty
acids (n3-PUFAs) in the diet were calculated as the sum
of the content in foods of eicosapentaenoic acid (EPA),
docosapentaenoic acid (DPA), docosahexaenoic acid (DHA),
and 𝛼-linolenic acid (ALA). Total n-6 polyunsaturated fatty
acids (n6-PUFAs) were, instead, the sum of linoleic (LA)
and arachidonic acid (AA). Although, using the food diary
data, we assessed the average intake of sodium from foods,
we could not estimate the amount of salt added to the food
during cooking or at the table.Therefore, total sodium intake
was estimated by evaluating urinary sodium excretion.
The data obtained at the analysis of energy and nutrient
intake were compared with the reference values reported
in the guidelines of the Dietitian Association of Australia
that still represent the only comprehensive dietary guidelines
for kidney transplant patients [3]. In addition, we compared
the data obtained in our patients with values recommended
by K/DOQI guidelines for patients with stage I/II chronic
kidney failure (CKD) [1, 2] that are often used in the clinics
as the target for a correct nutritional status in kidney graft
recipients.
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2.4. Analytical Procedures. BUN, creatinine, glucose, total
cholesterol, HDL-chol, LDL-chol, triglycerides, albumin, cal-
cium, and phosphorus were determined by standard ana-
lytical techniques. Serum high-sensibility C-reactive protein
(hs-CRP) concentrationwas determined by a high-sensitivity
ELISA assay (Bender MedSystems, Vienna, Austria). The
lower detection limit was 3 pg/mL, and the overall intra-
assay coefficient of variation has been calculated to be 6.9%.
Interleukin 6 (IL-6) plasma concentrations were determined
by ELISA using a commercially available kit (Quantikine;
R&D Systems, Minneapolis, MN) as described elsewhere
[28].The lower detection limit of IL-6 assaywas<0.70 pg/mL,
and the coefficient of variation of both inter- and intra-assay
was <5%. All samples were analyzed in duplicate.
2.5. Data Analysis. Data are expressed as mean ± SD. The
statistical evaluation of the data was performed by Student’s
t-test for unpaired data in case of two group comparison or by
one-way ANOVA followed by the post hoc Bonferroni’s test
in case of multiple group comparisons. Pearsons 𝜒2 test was
used to compare prevalence among groups.The threshold for
significance was set at 𝑃 < 0.05. Data analysis was performed
with the Statistical Package for Social Science software suite
(IBM SPSS version 20.0) (IBM, New York, USA).
3. Results
A total of 96 kidney transplant recipients entered the study.
The main demographic and anthropometric characteristics
of these three groups of patients are reported in Table 1.
Seventy-one percent of them were males. At the time of
transplantation, 68.8% of patients had a normal BMI, 25.0%
were overweight, and 6.3% obese. When the study was per-
formed, approximately 7.2 ± 5.0 years after transplantation,
these percentages had changed to the following: 52.1%normal
weight (50 patients, 36 males and 14 females), 29.1% over-
weight (28 patients, 20 males and 8 females), and 18.8% obese
(18 patients, 12 males and 6 females). A higher weight and
BMI gain occurred in females compared to males during the
years after kidney transplantation (overall, 19.8±13.6%versus
6.4 ± 10.4% of pretransplant body weight, resp.; 𝑃 < 0.001).
When we evaluated the body composition, we found that
the percent of fat mass and the percent of free fat mass
were significantly higher in OB than in OW and NW, and
in OW than in NW patients. Sixty-eight percent of male
and 64% of female patients showed higher WHR values than
normal.Whenwe examined the distribution of these patients
across the three different BMI categories that we defined in
Section 2, we found that WHR was higher than normal in
50% of male and 43% of female NW, in 90% of male and
75% of female OW, and in 83% of male and 100% of female
OB. No significant difference was observed in extracellular
water and TBW/FFM ratio, whereas body cell mass was
higher in OB and OW than in NW patients (Table 1).
There was no significant difference among the groups in the
immunosuppressive regimen assumed by the patients. All
patients were treated with 4mg/day methylprednisolone plus
tacrolimus (𝑛 = 38) or cyclosporine (𝑛 = 54) in addition to
steroids. In 76 patients, the immunosuppressive protocol also
Table 1: Demographic, anthropometric, and body composition data
and the pharmacological of treatment the three groups of kidney
transplant recipients divided according to BMI.
NW
𝑛 = 50
OW
𝑛 = 28
OB
𝑛 = 18
Male/female 36/14 20/8 12/6
Age, years 51.5 ± 10.4 48.7 ± 8.5 50.3 ± 10.1
Transplant time, years 7.8 ± 5.1 5.6 ± 4.3 7.9 ± 5.5
Pretransplant BW, Kg 58.2 ± 12.0 66.6 ± 9.4∗ 74.4 ± 12.1∗
Pretransplant BMI, Kg/m2 21.6 ± 2.9 24.2 ± 2.3∗ 28.2 ± 3.2∗∧
BW, Kg 60.5 ± 9.3 74.5 ± 36.7∗ 87.7 ± 11.7∗∧
BMI, Kg/m2 22.5 ± 2.0 27.2 ± 1.3∗ 33.3 ± 3.2∗∧
ΔBW, % of pre-transplant
BW 5.6 ± 11.8 13.0 ± 11.5
∗ 19.0 ± 12.6∗
TBW, % BW 59.4 ± 6.3 54.8 ± 4.9∗ 47.9 ± 3.8∗∧
ECW, % TBW 45.6 ± 3.9 43.9 ± 4.8 44.2 ± 4.4
FM, % BW 19.9 ± 8.7 25.5 ± 6.4∗ 35.6 ± 6.7∗∧
FFM, % BW 80.0 ± 8.7 74.4 ± 6.4∗ 64.4 ± 6.7∗∧
BCM, Kg 25.4 ± 5.8 30.0 ± 6.1∗ 29.5 ± 5.7∗
TBW/FFM 0.74 ± 0.02 0.73 ± 0.01 0.74 ± 0.02
Systolic blood pressure
(mmHg) 126 ± 11 130 ± 14 128 ± 8
Diastolic blood pressure
(mmHg) 80 ± 7 81 ± 3 80 ± 5
Cumulative corticosteroid
dose (g) 10.8 ± 8.5 8.1 ± 6.4 8.9 ± 8.1
Oral antidiabetic
drugs/Insulin therapy (%) 0/4 14/0 0/22
Lipid-lowering therapy (%) 52 71 78
Antihypertensive therapy
(%) 100 100 100
BW: body weight; BMI: body mass index; FM: fat mass; FFM: fat-free mass;
TBW: total body water; ECW: extracellular water; BCM: body cell mass.
∗
𝑃 < 0.05 versus NW; ∧𝑃 < 0.05 versus OW; ANOVA (with Bonferroni’s
posttest).
included mofetil mycophenolate. There was no significant
difference in the cumulative dose of steroids assumed by the
patients of the three groups (Table 1). Two patients treated
with CYA and none of those receiving FK experienced
acute rejection episodes during the study. The percentage of
patients assuming lipid-lowering or antidiabetic drugs was
significantly higher in OB and OW than in the NW groups
(78%, 71%, and 52%; 4%, 14%, and 22%; resp.).
Table 2 shows daily energy and nutrient intake of the 3
groups of patients (by BMI category) compared to dietary
reference intakes. Total energy intake was significantly higher
in OB than in NW, but in all the groups both energy
and protein intake, however expressed, were higher than
recommended by guidelines [1, 3, 5, 7–9]. Carbohydrates
(CHO) intake, conversely, was in the suggested range [4, 5,
8, 9] in all the groups, although a significant difference was
observed between NW and OW (53.8 ± 4.2%, versus 50.3 ±
6.1% of total energy intake, 𝑃 < 0.05, ANOVA).
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Table 2: Daily energy and nutrient intake of the 3 groups of patients (by BMI category) compared to the recommended daily intake (DRI).
NW: normal weight, OW: overweight, OB: obese.
NW
𝑛 = 50
OW
𝑛 = 28
OB
𝑛 = 18
DRI∧
Energy intake (Kcal/day) 1995 ± 282 2126 ± 264 2216 ± 358∗ —
Energy intake (Kcal/Kg∘/day) 32.9 ± 4.9 33.9 ± 4.0 35.5 ± 6.8 25–30a,c,e,g,h,i
Protein# (% kcal/day) 15.4 ± 1.4 15.7 ± 2.6 15.2 ± 1.0 —
Protein# (g/Kg∘/day) 1.27 ± 0.2 1.32 ± 0.2 1.38 ± 0.2 0.8–1.0a,c,e,g,h,i
Protein§ (g/Kg∘) 1.20 ± 0.2 1.25 ± 0.2 1.29 ± 0.3 —
Carbohydrates (% kcal/day) 53.8 ± 4.2 50.3 ± 6.1∗ 51.6 ± 4.7 50–60d,e,h,i
Total Fat (% kcal) 28.9 ± 3.4 31.9 ± 6.5∗∗ 31.3 ± 2.8∗ 25–35a,b,c,d,e,g,i; <30h;
Saturated fat (% kcal/day) 7.8 ± 1.3 8.9 ± 1.9∗ 8.2 ± 1.3 <7a,d,i; <8c; <10g,h
Monounsaturated fat (% kcal/day) 16.1 ± 2.1 17.5 ± 3.5 17.3 ± 1.9 >20b,c,d,i; 10–15h
Polyunsaturated fat (% kcal/day) 3.2 ± 0.2 3.6 ± 0.9∗∗ 3.7 ± 0.7∗∗ >10b,d,h,i
Omega 3 (% kcal/day) 0.50 ± 0.1 0.57 ± 0.1∗ 0.52 ± 0.1 —
Omega 3 (g/day) 1.12 ± 0.2 1.34 ± 0.4∗∗ 1.27 ± 0.3 2-3c,f
Omega 6 (% kcal/day) 2.67 ± 0.3 3.00 ± 0.9 3.15 ± 0.7∗ 8–10c
Omega 6 (g/day) 5.94 ± 1.3 7.12 ± 2.5∗ 7.89 ± 2.7∗∗ 10f
Omega 6/Omega 3 5.41 ± 1.3 5.62 ± 2.1 6.38 ± 2.3 1/1 to 4/1j
Fiber (g/day) 21.3 ± 5.9 20.8 ± 5.5 25.1 ± 8.3 20–30b,c,d,h,i
Cholesterol intake (mg/day) 169.5 ± 55.9 185.2 ± 49.1 171.7 ± 76.8 <200b,d; <300h
Food sodium intake# (mg/day) 1750 ± 601 1892 ± 559 2171 ± 671 —
Total NaCl intake§ (g/day) 10.3 ± 4.2 11.3 ± 3.4 12.7 ± 3.1 6–8c,e,h; <6d,k
Calcium (mg/day) 663 ± 170 747 ± 207 710 ± 158 800–1500c,g,h
Phosphorus (mg/day) 1112 ± 242 1237 ± 247 1188 ± 212 1200–1500g,h
∘kg of ideal weight; #estimated by diet record; §evaluated by urinary excretion of NaCl or Urea; ∧DRI: dietary reference intakes; ∗𝑃 < 0.05 versus NW, ∗∗𝑃 <
0.01 versus NW.
a[1], b[2], c[3], d[4], e[5], f[6], g[7], h[8], i[9], j[53] k[25].
In all the BMI groups, total fat intake was close to that
recommended by guidelines [1–5, 7–9]. However, it was
higher in OW and OB groups compared to NW group.
Relevant discrepancies fromguidelineswere observed in fatty
acid composition of the diet: in fact, in all the BMI groups,
saturated fatty acids intake was higher, while monounsatu-
rated and polyunsaturated fatty acids intake was lower than
the recommended intake [1–5, 7–9]. The intake of saturated
fatty acids was higher in OB and OW than in NW (𝑃 < 0.05
OW versus NW). Concerning the intake of polyunsaturated
fatty acids, in all patients n-6 and n-3 PUFA intakes were
both lower than the recommended values [3, 6] with a ratio
n-6/n-3 being remarkably high in all the groups (>5.4) and
particularly in OB group (6.38 ± 2.3). A positive correlation
between weight gain and both fat (𝑟 = 0.28; 𝑃 < 0.005) and
energy (𝑟 = 0.25; 𝑃 < 0.013) intake was observed.
Although the average intake of sodium from foods was
assessed, it was not possible to measure the amount of salt
added to the food during cooking or at the table. However,
total sodium intake was estimated from urinary sodium
excretion. Total salt intake was high [3–5, 8], exceeding
10 g/day in all groups. Dietary fiber intake was lower than
those recommended by guidelines [2–4, 8, 9] in all groups,
and particularly in NW and OW groups. Dietary intakes
of calcium and phosphorus resulted lower than the recom-
mended intake [3, 7, 8] in all groups.
Table 3 illustrates some biochemical parameters of the
groups under study. Noticeably, OB patients showed higher
signs of systemic inflammation. Indeed, circulating levels of
IL-6 and hs-CRP were significantly higher in the OB than
in the NW group. Moreover, serum hs-CRP was positively
correlated with WHR (𝑟 = 0.26; 𝑃 = 0.012). All the
groups showed high triglycerides plasma levels according to
the National Cholesterol Education Program (NCEP) Adults
Treatment Panel III (ATP III) criteria [4], but no further dif-
ference was observed in other parameters (Table 3). Because
it has been reported that plasma lipoprotein profile and
glycaemia are differentially affected by CYA and FK [29],
we compared these laboratory parameters in patients of our
series assuming these twodifferent drugs.Theonly significant
difference was in LDL-cholesterol plasma level that was
significantly lower in CYA-treated patients. However, signifi-
cantly, more patients were also assuming lipid-lowering and
antidiabetic drugs in the subgroup of subjects receiving CYA
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Table 3: Biochemical parameters and inflammatory markers (hs-CRP and IL-6) in the three groups of kidney transplant recipients (NW:
normal weight, OW: overweight, OB: obese).
NW
𝑛 = 50
OW
𝑛 = 28
OB
𝑛 = 18
eGFR∘ (mL/min) 50.8 ± 19.4 54.1 ± 13.2 63.0 ± 25.2
Plasma glucose (mg/dL) 77.7 ± 9.1 81.3 ± 15.0 82.9 ± 17.6
Plasma total cholesterol (mg/dL) 188.9 ± 33.5 181.0 ± 25.2 185.9 ± 31.4
Plasma HDL cholesterol (mg/dL) 49.4 ± 11.7 55.0 ± 14.9 50.0 ± 19.5
Plasma LDL cholesterol (mg/dL) 107.5 ± 34.9 96.3 ± 19.9 105.4 ± 30.4
Plasma tryglycerides (mg/dL) 153.5 ± 74.2 157.0 ± 46.8 154.3 ± 63.0
Serum uric acid 6.2 ± 0.7 6.3 ± 1.1 5.9 ± 1.0
Calcium (mg/dL) 9.7 ± 0.5 9.9 ± 0.4 9.6 ± 0.2
Phosphorus (mg/dL) 3.4 ± 0.8 3.2 ± 0.4 3.3 ± 0.4
Albumin (g/dL) 4.4 ± 0.3 4.5 ± 0.2 4.5 ± 0.3
hs-CRP (mg/L) 2.7 ± 2.4 4.0 ± 3.7 4.8 ± 3.9∗
IL-6 (pg/mL) 4.5 ± 3.2 5.0 ± 4.4 7.3 ± 5.0∗
Fibrinogen (mg/dL) 377.1 ± 123.4 326.0 ± 45.7 372.9 ± 101.1
∘Glomerular filtration rate (expressed by MDRD formula).
∗
𝑃 < 0.05 versus NW.
than in those treated with FK (67% versus 53%, and 16%
versus 7%, resp.).
4. Discussion
The main finding of the present work is that in long-term
renal transplant patients, dietary intake differs from guideline
recommendations because of a higher-energy and saturated
fat intake, a lower unsaturated, n-6, and n-3 PUFA, and fiber
consumption. These discrepancies from nutritional recom-
mendations are associatedwith a higher prevalence of obesity,
with high systemic inflammation, and with a higher assump-
tion of cardiovascular, lipid-lowering, and antidiabetic drugs.
At the time of the study, approximately 7 years after
transplantation, mean body weight of our patients was
10.3% higher than pretransplant values. The prevalence of
obesity in our patient population was 18.8% consistent with
previous reports [30]. Our study shows that the prevalence
of obesity in the renal transplant population is higher than in
general population (approximately 11% in Italy) [31]. Previous
studies suggested that the high prevalence of obesity after
kidney transplantation may depend on an excessive food
intake. This may be caused in renal allograft recipients by
different factors including the increased appetite induced
by glucocorticoids, the increased feeling of well-being, and
the fact that patients stop assuming the strict dialysis diet
to switch to an unrestricted diet. In keeping with this
hypothesis, we found that in our patients the energy intake
exceeded the values recommended by current nutritional
guidelines (25 to 30 kcal/kg/day) [1, 3, 5, 7–9]. Moreover, we
observed a strong correlation between total energy intake
and the increase in body weight that occurred during the
years after transplantation before the beginning of the study.
These data further support the idea that excessive energy
intake contribute to obesity after renal graft. In our renal
transplant recipients, most of fat accumulation that occurs
after kidney transplantation seems to be of the abdominal
type as indicated by the high prevalence of patients with
higher than normal WHR values. The evidence that visceral
fat accumulates in these patients could explain the close link
between obesity and inflammation thatwe found in our study.
Interestingly, not only hs-CRP and IL-6 concentrations were
higher in the OB subgroup but also a significant correlation
was found between WHR and hs-CRP. This suggests that the
accumulation of fat in general and especially of visceral fat
could have a role in causing systemic microinflammation in
kidney transplant recipients. This hypothesis is in agreement
with previous data from our group showing that visceral fat
contributes to increased plasma IL-6 and CRP in obesity
[32]. Importantly, both IL-6 and CRP are strong predictors
of all-cause and cause-specific cardiovascular mortality and
they can, at least in part account for the well-established
association between obesity, as defined on the basis of BMI,
and high blood pressure, and unfavorable lipid and glucose
metabolism profile [33]. Interestingly, WHR seems to be
a stronger predictor of cardiovascular risk than BMI [34].
Under this respect, it is worth mentioning that almost half
of our NW patients (50% of males and 43% of females) had a
higher than normalWHR and, therefore, they showed a “nor-
mal weight obesity”.This nosological entity has been recently
introduced to describe those patients that have a normal BMI
despite a higher than normal body fat content. Importantly,
normal weight obesity is associated with cardiovascular risk
factors and also with increased mortality [35–38].Therefore,
our findings suggest that lifestyle and nutritional interven-
tions could be helpful in kidney transplant recipients even
in the absence of overt obesity when WHR is higher than
normal. Such an approach could lead to a decrease in systemic
inflammation and, possibly, improve long-term prognosis.
Further studies on a larger patient population evaluated for
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a longer time will be necessary to strengthen this hypothe-
sis.
Little attention has been given in previous studies to the
different contribution of different nutrients to the increase
in energy intake in long-term transplant patients. In the
present study, we addressed this issue because it could have
important implications both in weight gain and in the risk
of cardiovascular complications and CAD. Although mean
total fat intake in our patients was within guideline recom-
mendations, there was a strong correlation between total fat
intake and the weight gain. The role of dietary fat intake
in the development of obesity after kidney transplantation
has not been studied before. Several studies evaluated its
involvement in the genesis of obesity in general population
yielding to controversial results. Indeed, some cross-sectional
studies found no association [39], whereas others reported
a positive association [40] between high-fat intake and
obesity. The results of the present study stand for a positive
relationship between fat intake and weigh it gain. Several
factors could account for this association. First, fat is the
most energy dense macronutrient. Second, fat provides a
lower satiety feeling, and its great flavor and palatability may
lead to a greater consumption of fatty foods. Dietary fat
intake composition in our patients differed from guidelines
because the content in saturated fat was higher and that in
monounsaturated and polyunsaturated fats was lower than
recommended. Moreover, the n-6/n-3PUFAs dietary ratio
was higher than current recommendations in all patients.The
excess in saturated fats coupled with the high n-6/n-3PUFAs
dietary ratio provides an additional risk for development
of cardiovascular diseases [41]. In addition, the association
between high n-6/n-3PUFAs dietary ratio and obesity may
account for the high IL-6 and hs-CRP that we found in our
OB patients [42]. These laboratory findings are an index
of systemic microinflammation, a condition occurring in
obesity where it contributes to increase cardiovascular risk
[43]. Importantly, systemic microinflammation is an auto-
maintaining process because it promotes further weight gain
that further worsen systemic inflammation [43, 44].
Another important difference that we found between the
nutrient composition of the diet of our long-term kidney
transplant recipients and that recommended in the guideline
was the higher content in protein intake. This could be rele-
vant as a causative factor forCAD. Indeed, high protein intake
may contribute to renal allograft injury [45] whereas a correct
intake of proteins may delay the course of chronic allograft
dysfunction, by reducing glomerular hyperfiltration [46].
Average CHO intake is close to that recommended in
Guidelines [4, 5, 8, 9] in all patients; we cannot exclude,
however, that obese patients have deliberately underreported
their real CHO intake [47].
Although we could not accurately measure total sodium
intake from dietary records, values estimated from the
measurement of sodium urinary excretion stand for an
intake substantially higher than recommended. This can be
due to the impaired ability of patients with kidney disease to
detect or taste salt in food [48] that makes them add much
more sodium than normal to improve food palatability. In
transplanted patients, dietary sodium may have important
effects on proteinuria, control of hypertension, and main-
tenance of an optimal volume status [49].
Finally, we found that daily dietary fiber intake in our
long-term renal allograft recipients was significantly lower
than recommended in guidelines [2–5, 8, 9, 50].The low-level
fiber consumption coupled with high-energy intake also put
these patients at risk for gaining weight or developing obesity
[51]. Several studies showed that a high fiber intake prevents
inflammation, metabolic syndrome, and cardiovascular dis-
eases, which are highly prevalent after RT [52].
The hypothesis that the obesity-associated discrepancies
in nutrient intake from recommendations in guidelines could
have a role in worsening the cardiovascular risk of these
subjects was supported by the evidence that the percent of
cardiovascular, antidiabetic, or lipid-lowering drug assump-
tion was higher in OB and OW than in NW patients.
Themajor limitation of our study is that we compared the
data on nutrient intake that we obtained from our patients
with those contained in guidelines that were not specifically
drawn for renal allograft recipients. Such guidelines, indeed,
are not available yet with the only exception of those of
the Dietitian Association of Australia in 2008 [3], and in
clinical practice the guidelines usually used are those for
stage I/II chronic kidney failure. The results of our study
showing the association between body weight gain, systemic
inflammation, and the use of multiple drugs in kidney trans-
plant recipients emphasize the need to plan further studies
with the aim of releasing official guidelines for nutritional
treatment of these patients. Another important limitation
is that our patients were all from southern Italy, and their
dietary habits could reflect regional variations and, therefore,
not be representative of the general behavior of kidney
transplant recipients.
In conclusion, we showed that nutrient composition
in long-term renal allograft recipients differs from recom-
mended values because of a higher protein, sodium, and
saturated fat and of a lower fiber and n-3 and n-6 polyunsat-
urated fat content. These discrepancies from guidelines are
associated with obesity, systemic inflammation, and higher
drug consumption.
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